Empagliflozin
|
|
|
- CAS-Nr.
- 864070-44-0
- Englisch Name:
- Empagliflozin
- Synonyma:
- Empaglifloin;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol;Glyxambi;mpagliflozin;EMPAGLIFLBZIN;Ipagliflozin;ozin;Empag;CS-798
- CBNumber:
- CB52627802
- Summenformel:
- C23H27ClO7
- Molgewicht:
- 450.91
- MOL-Datei:
- 864070-44-0.mol
|
Empagliflozin Eigenschaften
- Schmelzpunkt:
- 146-150°
- Siedepunkt:
- 665℃
- Dichte
- 1.398
- Flammpunkt:
- 356℃
- storage temp.
- 2-8°C
- L?slichkeit
- insoluble in H2O; ≥20.75 mg/mL in DMSO; ≥7.06 mg/mL in EtOH with ultrasonic
- Aggregatzustand
- solid
- pka
- 13.23±0.70(Predicted)
- Farbe
- White
- Optische Rotation
- 17.44°(C=0.50g/100mL, CD3OD, 20°C, 589nm)
- Stabilit?t:
- Hygroscopic
- InChIKey
- OBWASQILIWPZMG-QZMOQZSNSA-N
- SMILES
- C1=C(CC2=CC([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=CC=C2Cl)C=CC(O[C@H]2CCOC2)=C1
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H361 |
Kann vermutlich die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. |
Reproduktionstoxizit?t |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
| H362 |
Kann S?uglinge über die Muttermilch sch?digen. |
Reproductive toxicity, effects on or via lactation |
Additional category |
|
|
P201, P260, P263, P264, P270,P308+P313 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P263 |
Kontakt w?hrend der Schwangerschaft /und der Stillzeit vermeiden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P281 |
Vorgeschriebene pers?nliche Schutzausrüstung verwenden. |
| P308+P313 |
BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Empagliflozin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
was originally discovered by Boehringer Ingelheim and codeveloped
and co-marketed through research collaboration with
Eli Lilly and Co. It was first approved by European Medicine
Agency (EMA) in May 2014, followed by the approval of the US
FDA in August 2014. SGLT2 inhibitors are anewclass of glucose-lowering
agents developed for the treatment of type 2 diabetes mellitus,
which have a mechanism of action that is independent of pancreatic
b-cell function or the degree of insulin resistance. Consequently,
SGLT2 inhibitors have the potential to be of use not only as standalone
therapy but also in combination with any of the existing
classes of glucose-lowering agents, including insulin. Empagliflozin
selectively inhibits SGLT2, which in turn prevents glucose
reabsorption by excreting excess glucose in the urine.
Verwenden
Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
Definition
ChEBI: Empagliflozin is a C-glycosyl compound consisting of a beta-glucosyl residue having a (4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl group at the anomeric centre. A sodium-glucose co-transporter 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a sodium-glucose transport protein subtype 2 inhibitor and a hypoglycemic agent. It is a C-glycosyl compound, an aromatic ether, a tetrahydrofuryl ether and a member of monochlorobenzenes.
Mode of action
Empagliflozin is an orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Inhibition of SGLT2 in the kidneys also suppresses the renal reabsorption of 1,5-anhydroglucitol (1,5AG). This lowers serum 1,5AG and neutrophil 1,5-anhydroglucitol-6-phosphate (1,5AG6P) levels, which may improve neutropenia and neutrophil dysfunction in patients with glycogen storage disease type Ib (GSD Ib). SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.
pubchem.ncbi.nlm.nih.gov/compound/Empagliflozin
Empagliflozin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Empagliflozin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 761)Lieferanten
864070-44-0()Verwandte Suche:
- EMpagliflozin
- BI-10773
- EMpagliflozin/ BI-10773
- D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]M ethyl]phenyl]-, (1S)-
- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol Empagliflozin BI 10773
- Empagliflozin Impurity A
- (1S)-1,5-Anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-3-yl]oxy}phenyl)methyl]phenyl}-D-glucitol
- Boehringer Ingelheim(BI-44847)
- (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
- Empagliflozin whatsapp
- Empagliflozin(W.S)
- Empagliflozin API
- BI-10773;BI 10773;BI10773
- CS-798
- High purity CAS 129938-20-1 Dapoxetine hcl CAS NO.864070-44-0
- Empagliflozin CAS NO.864070-44-0
- Empagliflozin(BI10773,VA10802)
- Empag
- ozin
- (2S,3R,4R,5S,6R)-2-4-Chloro-3-4-(3S)-tetrahydrofuran-3-yloxyphenylmethylphenyl-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
- EmpagL
- Empagliflozin USP/EP/BP
- Empagli ozin
- Empagliflozin 13C6
- Empagliflozin D4Q: What is
Empagliflozin D4 Q: What is the CAS Number of
Empagliflozin D4 Q: What is the storage condition of
Empagliflozin D4 Q: What are the applications of
Empagliflozin D4
- (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol
- Glyxambi
- mpagliflozin
- Englejin
- 3-Piperidinecarboxylicacid,1-methoxy-10-oxo-,methylester
- 2H-1,4-Benzoxazine-7-carboxylicacid,3,10-dihydro-,methylester
- Empagliflozin,inhibit,Inhibitor,SGLT,BI-10773,Sodium-dependent glucose cotransporters,BI10773
- (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[4-[[(S)-3-tetrahydrofuranyl]oxy]benzyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
- Epalegin
- Empaglilozin
- Empagliflflozin
- Empagliflozin crystalline
- Englizin
- AJ93046
- CE0108
- CS0940
- PB23119
- VA10802
- Engeleijing
- Empagliflozin, 10 mM in DMSO
- Empagliflozin,99.5%min
- D4-(S)-Empagliflozin
- (1S)-1,5--1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucoseol
- Empagliflozin (Standard)
- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol
- EMPAGLIFLBZIN
- Empaglifloin
- Ipagliflozin
- 864070-44-0
- 964070-44-0
- 64070-44-0
- 765887-41-8
- C23H27ClO7
